GeoVax Labs, Inc. (GOVX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) Termination of President and Chief Executive Officer On November 5, 2026, David A. Dodd was terminated as President and

Event · Exec change
Person
David A. Dodd
Title
President and Chief Executive Officer
Action
terminated
Effective
effective immediately

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 6, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GOVX
Bearish
high confidence
Mentioned
$GOVX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GOVXBearishMed
01

Why it matters

CEO termination for cause is a governance shock that often leads to short‑term volatility and may affect ongoing clinical trial financing.

02

Market read

The filing is a primary disclosure of a leadership change, likely prompting immediate market reaction.

03

What to watch

Potential litigation over severance could create contingent liabilities not reflected in current price.

Relevance 6/10Novelty 7/10Timing: effective immediately, impact expected today

Background

GeoVax Labs (GOVX) is a clinical‑stage biotech focused on viral‑vector vaccines and immuno‑oncology.

Company-level read

Ticker impact

$GOVXBearishHigh confidence
Context

SEC Form 8‑K reports termination of CEO David A. Dodd for cause, a material corporate action.

Expected impact

likely downward pressure as market prices in leadership risk and potential litigation over severance.

Evidence & confidence

The filing is the first public disclosure of the CEO's departure, a key governance event that typically moves the share price.

Market effects

May raise concerns for biotech sector investors about governance risk.

Limited to U.S. market where GOVX trades.

Low, confined to the company.

Counterpoint

If the board swiftly appoints a seasoned biotech leader, the stock could rebound on confidence in new direction.

Key entities

  • David A. Dodd

    Outgoing President and CEO, terminated for cause.

  • GeoVax Labs, Inc.

    Biotech firm filing the 8‑K.

Related articles

$GOVXLow

EQS-News: GeoVax, Inc.: GeoVax Confirms Bundibugyo Ebola Vaccine Construct

GeoVax Labs, Inc. (GOVX) announced the development of a vaccine construct targeting Bundibugyo virus (BDBV) using its proprietary MVA-based rapid-cloning technology. The construct is a milestone toward a potential BDBV vaccine candidate, building on the company's existing filovirus vaccine portfolio. GeoVax's GEO-MVA vaccine for mpox and smallpox remains its primary focus, with a Phase 3 trial planned for late 2026. The World Health Organization (WHO) has called for accelerated development of BD

$GOVXMed

EQS-News: GeoVax, Inc.: GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study

GeoVax Labs (Nasdaq: GOVX) said it completed manufacturing, regulatory, clinical and preclinical milestones for its GEO-MVA pivotal Phase 3 immune-bridging study, scheduled to start in Q4 2026. The company expects a 500-participant trial and to report results in mid-2027, comparing GEO-MVA immune responses with licensed MVA-BN (Imvanex).

$GOVXMed

GeoVax Reports Second Quarter 2026 Financial Results

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_993355.htm EXHIBIT 99.1 ex_993355.htm Exhibit 99.1 GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update Company Advances GEO-MVA Toward Planned Pivotal Immunobridging Study Under Expedited Regulatory Pathway ATLANTA, GA, July 27, 2026 – G

$COSTHigh

The Best Recession-Proof Consumer Stock to Buy With $1,000 Before 2027

Costco (COST) reported Q4 2026 sales growth of 11.2%, with comparable sales up 9.4%. The company announced a $30 special dividend, its highest ever, boosting its stock by 5%. Costco's unique model, offering low prices and membership fees, drives loyalty and sales, especially during economic downturns. Gas stations and e-commerce are key growth drivers, with digitally-enabled sales up 20% YoY.

$MARAMed

MARA prices $185M debt offering after $1.1B Bitcoin sale

MARA priced an $185M debt offering at 8.75% interest, maturing in 2032, to finance its $1.5B acquisition of Long Ridge Energy. The deal includes a 485MW power plant and land for potential data centers. MARA recently sold $1.1B in Bitcoin to repay debt. Long Ridge generated $144M in annualized adjusted EBITDA, but interest payments may consume nearly half.